Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2325 January 2026

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number:		Fax Number:
Niraparib		
Initial application Applications from any relevant practitioner. Approvals valid for 6 months.  Prerequisites(tick boxes where appropriate)  Patient has advanced high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer  Patient has received at least one line** of treatment with platinum-based chemotherapy  and Patient has experienced a partial or complete response to the preceding treatment with platinum-based chemotherapy  Patient has not previously received funded treatment with a PARP inhibitor  Treatment will be commenced within 12 weeks of the patient's last dose of the preceding platinum-based regimen  Patient commenced treatment with niraparib prior to 1 May 2024  and Treatment to be administered as maintenance treatment  and Treatment not to be administered in combination with other chemotherapy		
and Treatment with niraparib to c	als valid for 6 months.	

I confirm the above details are correct and that in signing this form I understand I may be audited.

Note: \* "high-grade serous" includes tumours with high-grade serous features or a high-grade serous component.
\*\*A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments